Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$51.76 -1.5%	$46.82	$21.72 ▼ $52.85	$9.89B	1.23	3.00 million shs	3.00 million shs
ELAN Elanco Animal Health	$18.38 -0.4%	$15.55	$8.02 ▼ $18.87	$9.12B	1.66	7.71 million shs	71.27 million shs
GMTX Gemini Therapeutics	$59.65 0.0%	$57.60	$1.16 ▼ $14.10	$2.58B	-0.12	189,291 shs	214,790 shs
MRNA Moderna	$24.09 -1.6%	$29.09	$23.15 ▼ $79.96	$9.37B	1.83	9.44 million shs	8.27 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	+5.46%	+9.50%	+50.51%	+107.87%
ELAN Elanco Animal Health	0.00%	+2.69%	+34.22%	+36.52%	+20.65%
GMTX Gemini Therapeutics	-0.51%	-1.17%	+0.50%	+27.77%	+20.54%
MRNA Moderna	0.00%	-11.17%	-18.50%	-9.30%	-69.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.1645 of 5 stars	3.5	2.0	0.0	3.9	2.2	3.3	0.6
ELAN Elanco Animal Health	2.777 of 5 stars	2.4	2.0	0.0	0.3	2.6	1.7	1.3
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	4.5835 of 5 stars	4.0	2.0	0.0	4.6	2.7	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$62.18	20.12% Upside
ELAN Elanco Animal Health	2.78	Moderate Buy	$17.33	-5.67% Downside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
MRNA Moderna	2.04	Hold	$42.88	78.01% Upside

Current Analyst Ratings Breakdown

Latest GMTX, MRNA, BBIO, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $70.00
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $15.00
8/20/2025	ELAN Elanco Animal Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	ELAN Elanco Animal Health	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $18.00
8/8/2025	ELAN Elanco Animal Health	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $19.00
8/6/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $57.00
8/6/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $61.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	44.59	N/A	N/A	($9.30) per share	-5.57
ELAN Elanco Animal Health	$4.44B	2.06	$2.26 per share	8.14	$13.64 per share	1.35
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
MRNA Moderna	$3.24B	2.90	N/A	N/A	$24.16 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$4.09	N/A	N/A	N/A	-329.25%	N/A	-85.69%	11/11/2025 (Estimated)
ELAN Elanco Animal Health	$338M	$0.86	21.37	20.65	3.41	9.68%	7.04%	3.45%	11/6/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)

Latest GMTX, MRNA, BBIO, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ELAN Elanco Animal Health	$0.1989	$0.26	+$0.0611	$0.02	$1.19 billion	$1.24 billion
8/5/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.83	-$0.95	-$0.12	-$0.95	$98.46 million	$110.57 million
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	5.19	5.08
ELAN Elanco Animal Health	0.61	2.60	1.40
GMTX Gemini Therapeutics	N/A	71.49	71.49
MRNA Moderna	N/A	3.93	3.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
ELAN Elanco Animal Health	97.48%
GMTX Gemini Therapeutics	75.42%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
ELAN Elanco Animal Health	0.89%
GMTX Gemini Therapeutics	12.90%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	191.17 million	156.38 million	Optionable
ELAN Elanco Animal Health	9,000	496.81 million	492.39 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable

GMTX, MRNA, BBIO, and ELAN Headlines

Recent News About These Companies

Insider Buyers At Moderna Likely Disappointed With 11% Slide

August 30 at 12:26 PM | ca.finance.yahoo.com

FORA Capital LLC Acquires 23,344 Shares of Moderna, Inc. $MRNA

August 29 at 6:06 AM | marketbeat.com

FDA approves mRNA vaccines for new Covid-19 season amid political tension

August 28 at 8:47 PM | finance.yahoo.com

FDA Approves Updated COVID-19 Vaccines but With Restrictions

August 28 at 1:06 PM | zacks.com

Aristides Capital LLC Purchases Shares of 20,000 Moderna, Inc. $MRNA

August 28 at 8:19 AM | marketbeat.com

Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine

August 28 at 6:31 AM | insidermonkey.com

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

August 27, 2025 | accessnewswire.comA

Moderna (NASDAQ:MRNA) Stock Price Down 5.2% Following Analyst Downgrade

August 27, 2025 | marketbeat.com

Moderna, Inc. $MRNA Shares Sold by Groupe la Francaise

August 27, 2025 | marketbeat.com

“GPS” Molecules Help Maximize the Effectiveness of mRNA Vaccines

August 27, 2025 | technologynetworks.comT

Moderna, Inc. $MRNA Shares Bought by Northern Trust Corp

August 27, 2025 | marketbeat.com

Moderna (NASDAQ:MRNA) Stock Price Down 5.2% on Analyst Downgrade

August 27, 2025 | americanbankingnews.com

Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC

August 26, 2025 | marketbeat.com

Cresset Asset Management LLC Invests $522,000 in Moderna, Inc. $MRNA

August 26, 2025 | marketbeat.com

Option traders moderately bearish in Moderna with shares down 5.33%

August 26, 2025 | msn.com

How Moderna went from saving society to a shrinking share price

August 25, 2025 | theglobeandmail.com

Landmark Cancer Vaccines Face Delays Due to Robert F. Kennedy Jr.’s mRNA Cuts

August 25, 2025 | usnews.com

Jump Financial LLC Purchases 886,567 Shares of Moderna, Inc. $MRNA

August 25, 2025 | marketbeat.com

Health Canada approves Moderna’s updated Covid-19 mRNA vaccine, Spikevax, targeting SARS-CoV-2 variant LP.8.1

August 25, 2025 | pharmabiz.comP

Moderna’s updated Covid-19 vaccine gets Canadian approval

August 25, 2025 | finance.yahoo.com

Wellington Management Group LLP Reduces Stock Position in Moderna, Inc. $MRNA

August 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, MRNA, BBIO, and ELAN Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$51.76 -0.81 (-1.54%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$51.50 -0.26 (-0.50%)

As of 08/29/2025 07:28 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Elanco Animal Health NYSE:ELAN

$18.38 -0.08 (-0.41%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$18.50 +0.13 (+0.68%)

As of 08/29/2025 08:00 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Gemini Therapeutics NASDAQ:GMTX

$59.64 -0.02 (-0.03%)

As of 08/29/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Moderna NASDAQ:MRNA

$24.09 -0.38 (-1.55%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$24.16 +0.07 (+0.29%)

As of 08/29/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time